Estrogens in polycystic liver disease: A target for future therapies?

Sophie E. Aapkes, Lucas H. P. Bernts, Thijs R. M. Barten, Marjan van den Berg, Ron T. Gansevoort, Joost P. H. Drenth*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)
163 Downloads (Pure)

Abstract

Background and Aims Patients suffering from polycystic liver disease (PLD) can develop large liver volumes, leading to physical and psychological complaints, reducing quality of life. There is an unmet need for new therapies in these patients. Estrogen seems to be a promising target for new therapies. In this review, we summarize the available experimental and epidemiological evidence to unravel the role of estrogens and other female hormones in PLD, to answer clinical questions and identify new targets for therapy. Methods We identified all experimental and epidemiologial studies concerning estrogens or other female hormones and PLD, to answer pre-defined clinial questions. Results Female sex is the most important risk factor for the presence and severity of disease; estrogen supplementation enhances liver growth and after menopause, liver growth decreases. Experimental studies show the presence of the estrogen receptors alfa and beta on cystic cholangiocytes, and increased in vitro growth after administration of estrogen. Conclusions Based on the available evidence, female PLD patients should be discouraged from taking estrogen-containing contraceptives or hormone replacement therapy. Since liver growth rates decline after menopause, treatment decisions should be based on measured liver growth in postmenopausal women. Finally, blockage of estrogen receptors or estrogen production is a promising target for new therapies.

Original languageEnglish
Pages (from-to)2009-2019
Number of pages11
JournalLiver International
Volume41
Issue number9
Early online date10-Jul-2021
DOIs
Publication statusPublished - Sept-2021

Keywords

  • ADPKD
  • estrogen
  • GnRH analogues
  • polycystic liver disease
  • progesterone
  • tamoxifen
  • FOLLICLE-STIMULATING-HORMONE
  • KIDNEY-DISEASE
  • CHOLANGIOCYTE PROLIFERATION
  • RISK-FACTORS
  • CYST GROWTH
  • SOMATOSTATIN
  • LANREOTIDE
  • VOLUME
  • WOMEN
  • MANAGEMENT

Fingerprint

Dive into the research topics of 'Estrogens in polycystic liver disease: A target for future therapies?'. Together they form a unique fingerprint.

Cite this